Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1

We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-γ-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.

[1]  Yingnan Cao,et al.  Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses , 2007, Vaccine.

[2]  K. Yuen,et al.  Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity , 2007, Biochemical and Biophysical Research Communications.

[3]  Zheng-hong Yuan,et al.  Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. , 2007, Vaccine.

[4]  S. Kalams,et al.  Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. , 2007, AIDS research and human retroviruses.

[5]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[6]  Chetna Sharon,et al.  Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine , 2006, Vaccine.

[7]  P. Martín-Duque,et al.  Viral gene therapy , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[8]  S. Riffault,et al.  Porcine Innate and Adaptative Immune Responses to Influenza and Coronavirus Infections , 2006, Annals of the New York Academy of Sciences.

[9]  N. Jin,et al.  Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1. , 2006, Viral immunology.

[10]  K. Yuen,et al.  Modulation of the Unfolded Protein Response by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2006, Journal of Virology.

[11]  Ma Chunling,et al.  Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice , 2006, Intervirology.

[12]  S. Fry,et al.  Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice. , 2006, Journal of medical microbiology.

[13]  K. Yuen,et al.  Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines , 2006, Virology.

[14]  C. Andrews,et al.  Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  G. Kobinger,et al.  Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. , 2006, Human gene therapy.

[16]  M. Sung,et al.  Mucosal Immunization with Surface-Displayed Severe Acute Respiratory Syndrome Coronavirus Spike Protein on Lactobacillus casei Induces Neutralizing Antibodies in Mice , 2006, Journal of Virology.

[17]  J. Kleinschmidt,et al.  Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1 , 2006, Journal of Virology.

[18]  Zhimin Zhou,et al.  A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice , 2006, Vaccine.

[19]  M. Reiter,et al.  A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses , 2005, Vaccine.

[20]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[21]  M. Nikolova,et al.  The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients. , 2005, Cellular immunology.

[22]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Subbarao,et al.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.

[24]  D. Muruve,et al.  Immune responses to adeno-associated virus vectors. , 2005, Current gene therapy.

[25]  Wenlin Huang,et al.  Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats , 2005, Virus Research.

[26]  A. Roberts,et al.  A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. , 2005, The Journal of general virology.

[27]  Shibo Jiang,et al.  Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies , 2005, The Journal of Immunology.

[28]  Dong Yu,et al.  Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. , 2005, Vaccine.

[29]  B. Moss,et al.  Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein , 2005, Virology.

[30]  D. Ho,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.

[31]  Jingxin Cao,et al.  Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.

[32]  Y. Guan,et al.  Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice , 2004, Vaccine.

[33]  R. Proulx,et al.  Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.

[34]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[35]  S. Harper,et al.  Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Shuangli Li,et al.  Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. , 2004, DNA and cell biology.

[37]  B. Murphy,et al.  Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Murphy,et al.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.

[39]  B. Moss,et al.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[41]  E. Marshall,et al.  Caution Urged on SARS Vaccines , 2004, Science.

[42]  J. Yu,et al.  DNA Vaccine of SARS-Cov S Gene Induces Antibody Response in Mice , 2004, Acta biochimica et biophysica Sinica.

[43]  Y. Guan,et al.  Prophylactic and Therapeutic Effects of Small Interfering Rna Targeting Sars-Coronavirus , 2003, Antiviral therapy.

[44]  H. Weiner,et al.  Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[45]  E. Marshall,et al.  Medicine. Caution urged on SARS vaccines. , 2004, Science.

[46]  W. Bellini,et al.  Effects of a SARS-associated coronavirus vaccine in monkeys , 2003, The Lancet.

[47]  E. Lehtonen,et al.  Evaluation of risks related to the use of adeno-associated virus-based vectors. , 2003, Current gene therapy.

[48]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[49]  N. Chirmule,et al.  Long‐term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno‐associated viral vectors in mice , 2003, The journal of gene medicine.

[50]  J. Peiris,et al.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.

[51]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[52]  B. Bosch,et al.  The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.

[53]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[54]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[55]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.

[56]  R. Samulski,et al.  Identification and Characterization of an Adeno-Associated Virus Integration Site in CV-1 Cells from the African Green Monkey , 2003, Journal of Virology.

[57]  P. Woo,et al.  A single dose of oral DNA immunization delivered by attenuated Salmonella typhimurium down‐regulates transgene expression in HBsAg transgenic mice , 2002, European journal of immunology.

[58]  H. Mizukami,et al.  Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. , 2002, Human gene therapy.

[59]  W. Hiddemann,et al.  Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. , 2002, Blood.

[60]  R. Owens.  Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. , 2002, Current gene therapy.

[61]  Z. Xiang,et al.  Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product , 2002, Journal of Virology.

[62]  D. Curiel,et al.  Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo Immunotherapy , 2001, Journal of Virology.

[63]  K. Yuen,et al.  Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. , 2001, Vaccine.

[64]  H. Mizukami,et al.  A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. , 2001, Human gene therapy.

[65]  R. Samulski,et al.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  Christopher J. Miller,et al.  Mucosal Immunization of Cynomolgus Macaques with Two Serotypes of Live Poliovirus Vectors Expressing Simian Immunodeficiency Virus Antigens: Stimulation of Humoral, Mucosal, and Cellular Immunity , 1999, Journal of Virology.

[67]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.